GZ402671: cost and payments to doctors
What Medicare Part D paid pharmacies for GZ402671, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Sanofi-aventis U.S. LLC?
Sanofi-aventis U.S. LLC reported the most payments naming GZ402671. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $29K
- Providers
- 10
- Transactions
- 36
- Average per transaction
- $806
The per-transaction average — $806 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 10 providers the average total is $2,901, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi-aventis U.S. LLC | $25,956 | 89.5% |
| Sanofi US Services Inc. | $3,056 | 10.5% |
Other products from Sanofi-aventis U.S. LLC
The company that reported the most payments naming GZ402671 also reports against these.
- SOLIQUA 100/33$10,474,032
- TZIELD$8,855,550
- TOUJEO$6,172,887
- DUPIXENT$4,377,310
- MULTAQ$3,603,705
- PRALUENT$3,219,961
- THYMOGLOBULIN$2,596,054
- REZUROCK$1,969,127
- NO PRODUCT DISCUSSED$1,624,453
- AUBAGIO$523,272